Significant Accounting Policies (Details Textual) - USD ($) |
9 Months Ended | 12 Months Ended |
|---|---|---|
Sep. 30, 2016 |
Dec. 31, 2015 |
|
| Warrant [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 670,191 | |
| Fortress Biotech, Inc [Member] | ||
| Annual Fee On Diluted Outstanding Equity, Percentage | 2.50% | |
| Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | $ 190,000 | |
| Series A Preferred Stock [Member] | Preferred Shares [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 250,000 |
| X | ||||||||||
- Definition It represents the annual fee percentage on diluted outstanding equity. No definition available.
|
| X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The fair value of capitalized costs of a research and development nature that were acquired during the period in a transaction other than a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|